[
  {
    "ts": "2026-02-02T03:11:09+00:00",
    "headline": "Amgen (AMGN) Reports Q4: Everything You Need To Know Ahead Of Earnings",
    "summary": "Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after the bell. Here’s what to look for.",
    "url": "https://finance.yahoo.com/news/amgen-amgn-reports-q4-everything-031109924.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "1946a4c7-7143-343e-bfda-eba147bcdff6",
      "content": {
        "id": "1946a4c7-7143-343e-bfda-eba147bcdff6",
        "contentType": "STORY",
        "title": "Amgen (AMGN) Reports Q4: Everything You Need To Know Ahead Of Earnings",
        "description": "",
        "summary": "Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after the bell. Here’s what to look for.",
        "pubDate": "2026-02-02T03:11:09Z",
        "displayTime": "2026-02-02T03:11:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "AMGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cVRDvNeMN6SVWgnyfhcabA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/khfuGqTIKrJ0BdS6OOusRA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-reports-q4-everything-031109924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-reports-q4-everything-031109924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T11:59:11+00:00",
    "headline": "Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data",
    "summary": "Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.",
    "url": "https://www.pharmaceutical-technology.com/news/amgen-rocatinlimab-kyowa-kirin-agreement-termination-atopic-dermatitis/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "9318ecd1-10b5-3e11-a083-79a64171c43c",
      "content": {
        "id": "9318ecd1-10b5-3e11-a083-79a64171c43c",
        "contentType": "STORY",
        "title": "Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data",
        "description": "",
        "summary": "Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.",
        "pubDate": "2026-02-02T11:59:11Z",
        "displayTime": "2026-02-02T11:59:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/ca7574479e44160a49581d023d8f36b2",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Kyowa Kirin will regain control of the global programme for rocatinlimab in AD as Amgen terminates development and commercialisation agreement. Image credit: Antonina Vlasova via ShutterStock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h16VHlaLZkX1h1QQBG3Q1A--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/ca7574479e44160a49581d023d8f36b2.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BgLiXRYA2r1bY_ATeApRTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/ca7574479e44160a49581d023d8f36b2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/amgen-rocatinlimab-kyowa-kirin-agreement-termination-atopic-dermatitis/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-hands-back-eczema-drug-115911597.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "KYKOF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]